Drugs / NESBUVIR
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00410254 | Jun → Aug 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00500721 | Jun → Aug 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00407173 | Nov 2006 → Jun 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00385190 | Jul → Nov 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00314054 | May 2006 → Oct 2007 | hepatitis C virus infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00367887 Comparator | Oct 2006 → Jul 2008 | hepatitis C virus infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NESBUVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL1092581 ↗ |
| Known as | HCV-796 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00385190 ↗ |
| Modality | Small molecule | — CHEMBL1092581 ↗ |
| Route | Oral | “Capsules, 500 mg, Q 12 hrs. daily, 48 weeks” NCT00367887 ↗ |